• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Antiphospholipid Syndrome-induced Ischemic Stroke Following Pembrolizumab: case report and systematic review
We report a case of a patient treated with pembrolizumab who developed an acute ischemic stroke (AIS) as manifestation of immunotherapy-induced antiphospholipid syndrome (APS) and provide a systematic review of the literature.
Source: Lung Cancer - August 3, 2021 Category: Cancer & Oncology Authors: Vito Tota, Marie Dagonnier, Didier Wery, Laure Binet, Nathalie Nagy, Val érie Durieux, Marie Diaz, Jose-Antonio Elosegi, Stéphane Holbrechts Tags: Review Source Type: research

Recurrent stroke due to antiphospholipid syndrome remitted by immunotherapy, not by anticoagulation therapy: A case report and literature review
Jin-Mo Park, Kyung Yoon EahAnnals of Indian Academy of Neurology 2019 22(2):250-252
Source: Annals of Indian Academy of Neurology - April 8, 2019 Category: Neurology Authors: Jin-Mo Park Kyung Yoon Eah Source Type: research